A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke

Trial Profile

A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2018

At a glance

  • Drugs SB 623 (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Sponsors SanBio
  • Most Recent Events

    • 31 May 2018 According to a SanBio Group media release, this trial was addressed at an event held by California Institute for Regenerative Medicine (CIRM) on May 31, 2018.
    • 26 Jan 2018 Results assessing safety and clinical outcomes (two years) associated with surgical implantation of SB623 in patients with stable chronic ischemic stroke, presented at the International Stroke Conference 2018.
    • 24 Jun 2016 According to SanBio media release, interim (preliminary) results presented of this trial are presented at the International Society of Stem Cell Research Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top